Arrayit’s technologies could be used in order to expedite Omontys’ return to market.
Remember the article from "The Street" last March about OTCQB:ARYC "Arrayit's Potential as a Blockbuster Companion Diagnostic" where it said
"Arrayit’s technologies could be used in order to expedite Omontys’ return to market. The company’s blood cards could be used to sample blood from 25,000 patients at the point-of-care, which could then be input into its VIP technology for low-cost targeted genotyping. Meanwhile, its H25K could be used to perform whole genome expression profiling, while peptide microarrays could be used to test for patient antibodies.Essentially, Arrayit’s role as a companion diagnostic could help companies like Affymax get products like Omontys back on the market more quickly. And the same technology could be used to ensure patients are properly enrolled in clinical trials, confirm the right patients being treated with approved drugs, and assist other pharmaceutical companies in regaining regulatory compliance after a drug has been found unsafe in certain populations."
ARYC had this intriguing tweet a couple of days ago:
"Excited to have visitors from Japan coming in on the 4th. The new facilities really help us make a great first impression"
More from the article
AFFY "voluntarily pulled its anemia drug, Omontys, used to treat kidney dialysis, following news that 50 adverse reactions were discovered in 25,000 patients treated, including at least five deaths.The problem observed in these 50 patients was hypersensitivity – a sometimes-fatal condition that arises when the body’s immune system reacts to certain drugs or other intrusions, like bee stings, according to the Wall Street Journal. Since a relatively small patient population was tested in clinical trials, these side effects went unnoticed until the drug was exposed to a larger patient population, thereby leading to significant and unexpected shareholder losses.Ways to Improve OutcomesCompanion diagnostic tests are molecular assays that measure levels of proteins, genes or specific mutations in order to provide the right treatment to the right patient. In Affymax’s case, companion diagnostics could be used to ensure that the patient being treated was not hypersensitive to Omontys. This would thereby avoid adverse events, while providing the convenience-related benefits compared to Amgen Inc.’s (NASDAQ: AMGN) Epogen."